FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									all applic	cable) or	g Per	son(s) to Iss	wner				
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 01/04/2016									below)	(give title		Other (below)	specity
50 NORTHERN AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
BOSTON MA 02210				_										Form filed by More than One Reporting Person					
(City)	(Si	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					·	if any	emed ion Date, i/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Benefic		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Transac	Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 01/04/2				01/04/20	016	16					1,333	A	\$57	7.27	2,	,166		D	
Common Stock 01/04/201					016	16					925	D	\$122.	07 ⁽²⁾⁽³⁾ 1		1,241		D	
Common Stock 01/04/201				016	16		S ⁽¹⁾			200	D	\$122.	87(2)(4)	1,041			D		
		T	able								sposed of				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any	eemed Ition Date,	4. Transa Code (8)	5. Numbe		umber ivative urities uired or posed D) tr. 3, 4	6. Dat		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Do Se (Ir		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owi For Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	or Num of Sha	nber					
Stock Option	\$57.27	01/04/2016			M			1,333		(5)	09/13/2022	Commo		33	\$0.00	23,334	.]	D	

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- 2. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$122.07 (range \$121.51 to \$122.48).
- 4. Open market sales reported on this line occurred at a weighted average price of \$122.87 (range \$122.71 to \$123.03).
- 5. The option vests in 16 quarterly installments from 09/14/2012.

Remarks:

Omar White, Attorney-In-Fact 01/06/2016

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.